Skip to main content
BioNexus Gene Lab Corp logo

BioNexus Gene Lab Corp — Investor Relations & Filings

Ticker · BGLC ISIN · US0906283066 LEI · 549300COYSKRA3Z7E531 US Professional, scientific and technical activities
Open in API
Filings indexed 140 across all filing types
Latest filing 2026-06-05 Regulatory Filings
Country US United States of America
Listing US BGLC

About BioNexus Gene Lab Corp

https://www.bionexusgenelab.com/

BioNexus Gene Lab Corp. is a biotechnology company that specializes in precision diagnostics and gene-based technologies. The company focuses on the development and commercialization of advanced molecular diagnostics and genetic testing. Its core service involves non-invasive, blood-based dynamic genome screening for the early detection of an individual's susceptibility to certain diseases. Utilizing RNA research and screening facilities, BioNexus aims to identify health risks at their earliest stages to enable proactive health management.

Recent filings

Filing Released Lang Actions
FORM 8-K
Regulatory Filings Classification · 79% confidence The document is a US SEC Form 8-K “Current Report” primarily reporting an “Other Events” press release. It does not contain financial statements, earnings highlights, or substantive report content (e.g., 10-K, IR, ER, etc.), nor is it announcing a vote, dividend, management change, or M&A. It is a routine regulatory filing of a press release via Form 8-K, matching the fallback category for miscellaneous regulatory announcements.
2026-06-05 English
FORM 10-Q
Interim / Quarterly Report Q1 2026
2026-05-15 English
10-K - BioNexus Gene Lab Corp (0001737523) (Filer)
Annual Report FY 2025
2026-04-14 English
8-K - BioNexus Gene Lab Corp (0001737523) (Filer)
Regulatory Filings Classification · 95% confidence The document is a Form 8-K Current Report filed with the SEC, which is used for reporting unscheduled material events or corporate changes. The content includes a press release about the appointment of a new Chief Commercial Officer for a subsidiary company, Fidelion Diagnostics, and does not contain financial statements or detailed financial data. The document length is 3822 characters, which is relatively short and primarily serves as a disclosure of a corporate event rather than a full report. There is no indication of financial results, audit information, or other report types. Therefore, this filing is best classified as a Regulatory Filing (RNS), which is the fallback category for miscellaneous filings that do not fit other specific categories.
2026-03-17 English
8-K - BioNexus Gene Lab Corp (0001737523) (Filer)
Board/Management Information Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce unscheduled material events or corporate changes. The content describes a governance restructuring of a subsidiary, Chemrex Corporation, including changes in its board of directors. There is no financial data or detailed financial performance information, so it is not an Annual Report (10-K) or Interim Report (IR). It is not a full management report or earnings release. The focus is on changes in the board of directors of a subsidiary, which aligns with Board/Management Information filings. The document is 4442 characters, which is relatively short but contains substantive information about management changes, not just an announcement of a report publication. Therefore, the best classification is Board/Management Information (MANG).
2026-02-23 English
8-K Filing
Regulatory Filings Classification · 95% confidence The document is a Form 8-K Current Report filed with the SEC, which is used to announce major events or other significant information about the company. The text describes a press release announcing the commencement of a regional deployment phase for a product, along with strategic objectives and commercialization steps. There are no financial statements or detailed financial data included. The document is relatively short (4296 characters) and primarily serves as an announcement of an event and a press release. Therefore, it is not an Annual Report, Earnings Release, or Interim Report. It is also not a Management Report or Investor Presentation. The document fits best as a Regulatory Filing (RNS), which is the fallback category for miscellaneous filings that do not fit other specific categories.
2026-02-03 English

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.